|
Immunotherapy In Allergic Rhinitis - Moving Away From InjectionsPublished by: Datamonitor Published: Apr. 12, 2006 Table of Contents
AbstractIntroductionAllergic rhinitis affects between 15% and 20% of the population in the seven major markets. Currently available treatments focus on symptom relief; however, a significant number of allergic rhinitis patients with uncontrolled symptoms remain. Shorter, safer, and more convenient therapies currently in development may lead to a substantial market expansion. Scope of this report
The prevalence of allergic rhinitis in the seven major markets ranges from 7.9% (Spain) to 17.2% (France), but only about half of the affected population currently seek treatment. Immunotherapy is dominated by a few regional players, constituting a small niche within the EUR 16 billion allergic rhinitis market. Several small companies are developing immunotherapy products with likely competitive advantages over currently available products. The aim is to achieve shorter sublingual immunotherapy courses. Key reasons to read this report
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||